Information Provided By:
Fly News Breaks for October 29, 2018
Oct 29, 2018 | 07:44 EDT
Leerink analyst Richard Newitter started Inspire Medical with an Outperform rating and $57 price target. The analyst sees it as a sustainable ultra high-growth/gross margin small-cap as the company drives higher utilization of its first and only FDA-approved neurostimulation device for obstructive sleep apnea, where current therapies have drawbacks and Inspire Medical's unique solution can offer patient benefits over them.
News For INSP From the Last 2 Days
There are no results for your query INSP